Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.72 |
| ▸ | PPARG | P37231 | 12/20 | 0.72 |
| ▸ | PPARA | Q07869 | 12/20 | 0.72 |
| ▸ | NR1H2 | P55055 | 12/20 | 0.72 |
| ▸ | NR1H3 | Q13133 | 12/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063144 | 0.94 | PPARD (0.71) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL4063560 | 0.93 | PPARD (0.69) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL4053978 | 0.90 | NR1H3 (0.64) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL4060698 | 0.88 | PPARG (0.64) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL4054594 | 0.88 | PPARG (0.65) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL4055211 | 0.86 | NR1H3 (0.65) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL4065858 | 0.84 | NR1H3 (0.66) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL4236162 | 0.83 | PPARG (0.71) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL4063594 | 0.83 | NR1H3 (0.65) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL4064059 | 0.83 | NR1H3 (0.62) | PPARDPPARGPPARANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964622-B2 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | MA XIN | 2009-12-03 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592361-B2 | (5-{3-[4-(4,5,6,7-tetrahydro-benzooxazol-2-yl)-phenoxy]-propoxy}-indol-1-yl)-acetic acid; diabetes, obesity, hyperlipidemia, and atherosclerotic disease | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1689389-A4 | INDOLE COMPOUNDS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2009-06-17 | — | — | EP | disclosed |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | BAYER HEALTHCARE LLC | 2006-11-23 | — | — | US | disclosed |
| EP-1689389-A2 | INDOLE COMPOUNDS | National Health Research Institutes (TW) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005056522-A2 | INDOLE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298854-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARD 452/4885PPARG 347/4885PPARA 243/4885 |
| US-20060264486-A1 | Indole acetic acid derivatives and their use as pharmaceutical agents | IDO1, IDO2, AADAT | PPARD 452/4885PPARG 347/4885PPARA 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.